Clinical Trial Update: Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study of magrolimab combinations in relapsed/refractory multiple myeloma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Magrolimab (magrolimab)

Snippet

Sponsor: Gilead Sciences | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2025-05-02